Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)
France flag France · Delayed Price · Currency is EUR
0.586
-0.052 (-8.15%)
At close: Mar 6, 2026

EPA:ALOPM Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Operating Revenue
0.210.221.48.02
Other Revenue
1.531.420.340.27
Revenue
1.741.641.748.29
Revenue Growth (YoY)
31.93%-6.02%-79.03%-
Cost of Revenue
-7.576.5187.56
Gross Profit
9.31-4.88-6.260.73
Selling, General & Admin
2.752.593.312.08
Other Operating Expenses
0.080.080.120.1
Operating Expenses
3.132.933.692.34
Operating Income
6.18-7.81-9.94-1.61
Interest Expense
-0.43-0.44-0.15-0.12
Interest & Investment Income
0.140.30.240
Currency Exchange Gain (Loss)
-0-0-0.020
Other Non Operating Income (Expenses)
-0--0
EBT Excluding Unusual Items
5.88-7.95-9.86-1.72
Gain (Loss) on Sale of Investments
-0.04-0.020.01-
Other Unusual Items
-0.34-0.350-0
Pretax Income
5.51-8.31-9.85-1.72
Income Tax Expense
-0.76-1.1-1.76-1.49
Net Income
6.27-7.21-8.09-0.23
Net Income to Common
6.27-7.21-8.09-0.23
Shares Outstanding (Basic)
18181717
Shares Outstanding (Diluted)
18181717
Shares Change (YoY)
-9.16%-0.48%-
EPS (Basic)
0.35-0.40-0.49-0.01
EPS (Diluted)
0.35-0.40-0.49-0.01
Gross Margin
535.56%-298.27%-8.84%
Operating Margin
355.52%-477.48%-571.55%-19.41%
Profit Margin
360.70%-440.94%-465.04%-2.79%
EBITDA
6.48-7.55-9.69-1.45
EBITDA Margin
372.74%---17.43%
D&A For EBITDA
0.30.260.250.16
EBIT
6.18-7.81-9.94-1.61
EBIT Margin
355.52%---19.41%
Revenue as Reported
1.741.641.758.32
Source: S&P Capital IQ. Standard template. Financial Sources.